In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Do the patients with coronary artery disease have the same benefits from transcatheter aortic valve implantation?

Session Poster Session 1

Speaker Paulo Maia Araujo

Congress : Heart Failure 2018

  • Topic : valvular, myocardial, pericardial, pulmonary, congenital heart disease
  • Sub-topic : Valvular Heart Disease - Treatment
  • Session type : Poster Session
  • FP Number : P510

Authors : PM Araujo (Porto,PT), A Nunes (Porto,PT), S Torres (Porto,PT), M Braga (Porto,PT), R Pinto (Porto,PT), J Rodrigues (Porto,PT), RA Rodrigues (Porto,PT), PB Almeida (Porto,PT), MB Campelo (Porto,PT), JC Silva (Porto,PT), MJ Maciel (Porto,PT)

PM Araujo1 , A Nunes1 , S Torres1 , M Braga1 , R Pinto1 , J Rodrigues1 , RA Rodrigues1 , PB Almeida1 , MB Campelo1 , JC Silva1 , MJ Maciel1 , 1Sao Joao Hospital, Cardiology - Porto - Portugal ,


Introduction: Transcatheter aortic valve implantation (TAVI) is an effective treatment for symptomatic severe aortic stenosis, considered at high surgical risk. Coronary artery disease (CAD) is a frequent comorbidity in these patients (pts) and can influence the results of this procedure.

Purpose: To evaluate if the beneficial effects of TAVI on morbi/mortality and on the symptoms improvement are comparable in patients with or without CAD.

Methods: We retrospectively evaluated pts submitted to TAVI in our hospital between October 2014 and December 2016. All pts had symptomatic severe aortic stenosis prior to the procedure and the decision for referral for TAVI was made by a multidisciplinary Heart Team. CAD was defined as the presence of obstructive lesions (any stenosis =70% or left main [LM] stenosis =50%).

Results: During this period, 89 pts were submitted to TAVI, with a mean age of 80.2±7.1 years, of whom 51.7% (n=46) were female. Forty two pts (47.2%) had CAD: one vessel in 19.1%; 2 vessels in 4.5%; 3 vessels in 5.6%; involvement of LM in 33%. Of this group, 47.6% had been previously submitted to PCI and 35.7% to CABG. Additionally, in fifteen pts (35.7% of CAD group) periprocedural PCI was performed.
Baseline characteristics weren’t significantly different between pts with/wihout CAD regarding to age (81.1 vs 79.5 years; p=0.69), sex (45.2% vs 57.4% female; p=0.25), left ventricular ejection fraction (55.0% vs 50.7%; p=0.66), NYHA class =2 (97.6% vs 100%; p=0.29) or presence of angina (26.2% vs 14.9%; p=0.19). As expected, EuroScore II was higher in CAD pts (7.8% vs 3.8%; p<0.01).
Incidence of intra/postprocedural complications was similar between CAD pts vs no CAD: 64.3% vs 68.1% (p= 0.71). However, mean stay was higher in CAD pts (15.3 vs 12.4 days; p= 0.01). Only one patient had in-hospital mortality (no CAD).
During a mean time of follow-up of 386±93 days after discharge, CAD pts had similar rates of all-causes mortality (9.8% vs 4.3%, p=0.32), but cardiovascular mortality was tendentially higher (7.3% vs 0%), although not reaching statistical significance (p=0.06).
CAD group had higher rates of hospitalizations: 39.0% vs 19.6% (p=0.05).
At one year after discharge, in the CAD group, TAVI resulted in a significant reduction of angina (pre-TAVI: 26.2% vs post-TAVI 5.7%; p<0.01) and of NYHA class =2 (pre-TAVI: 97.6% vs post-TAVI 37.1%; p<0.01). The proportion of pts reporting an overall improvement on functional capacity after the procedure was high, with similar rates between pts with or without CAD: 85.7% vs 76.7% (p=0.32).

Conclusion: In this population, the presence of CAD was associated with higher morbidity and a tendency to higher cardiovascular mortality after TAVI. However, this procedure successfully improved symptoms and functional capacity in CAD group,  similarly to the other pts. Therefore, TAVI has important clinical benefits even in pts with CAD.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are